Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients. [clinicaltrials:NCT00219388]

Bio2RDF identifier

NCT00219388

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00219388

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00219388

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:64fd394d10a2f5e0b93e526fba35ffe7

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... severe chronic heart failure.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy and Safety of Treatme ...... nsated Heart Failure Patients.

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Compare the hemodynamic parameters Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) from baseline to 24 hours, between the two groups. [clinicaltrials_resource:3796067125e38fd7b5ffb845ff83a8f8]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Compare the hemodynamic parameters Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) from baseline to 24 hours, between the two groups. [clinicaltrials_resource:32453500b648ea71ce2e9c9c21a469bb]

Compare the hemodynamic parameters Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) from baseline to 24 hours, between the two groups. [clinicaltrials_resource:3547339a57d58d64f3efa89d1f64abaf]

Compare the hemodynamic parameters Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) from baseline to 24 hours, between the two groups. [clinicaltrials_resource:68444088236828d30095f1d99a8d639e]

Compare the hemodynamic parameters Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) from baseline to 24 hours, between the two groups. [clinicaltrials_resource:89d80eaba8e00b737ec00424636d595e]

Compare the hemodynamic parameters Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) from baseline to 24 hours, between the two groups. [clinicaltrials_resource:8b2ccc96ba30e347d7ff323d5e79aba7]

Compare the hemodynamic parameters Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) from baseline to 24 hours, between the two groups. [clinicaltrials_resource:95738318cec1fd8daa4a1981a036fbd7]

Compare the hemodynamic parameters Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) from baseline to 24 hours, between the two groups. [clinicaltrials_resource:95990b8584c9d80ed1da3285355daa1b]

Compare the hemodynamic parameters Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) from baseline to 24 hours, between the two groups. [clinicaltrials_resource:fb9f1e74387997fe8d3259c9e0d0fcc0]

completion date [clinicaltrials_vocabulary:completion-date]

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Patients with decompens ...... ng the past 30-35 days.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00219388 [clinicaltrials_resource:db1c5c75184eaf8d19e2d18cf5898008]

enrollment [clinicaltrials_vocabulary:enrollment]

60

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Levosimendan [clinicaltrials_resource:b892608f59c442bd7f4246b3d8fbd2e2]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Simendan [clinicaltrials_resource:5344640ba43eb9ddc3503874c9fd6514]

keyword [clinicaltrials_vocabulary:keyword]

Decompensated Heart Failure

http://www.w3.org/2001/XMLSchema#string

Dobutamine

http://www.w3.org/2001/XMLSchema#string

Efficacy

http://www.w3.org/2001/XMLSchema#string

Intravenous

http://www.w3.org/2001/XMLSchema#string

Invasive hemodynamics

http://www.w3.org/2001/XMLSchema#string

Levosimendan

http://www.w3.org/2001/XMLSchema#string

Safety

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2005-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Orion Corporation, Orion Pharma [clinicaltrials_resource:56914c11ae481d6452d21ddca88db97d]

location [clinicaltrials_vocabulary:location]

Cardiology Department, Sahlgrenska University Hospital [clinicaltrials_resource:0276fbc13893cb70cb853a41aa486f65]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00219388

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

Efficacy and Safety of Short-T ...... Beta-Receptor Blocking Agents.

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

3.001.075

http://www.w3.org/2001/XMLSchema#integer

overall official [clinicaltrials_vocabulary:overall-official]

Claes-Håkan Bergh, Assoc Prof [clinicaltrials_resource:048c1ff0e97fd5d6f3beeafbbc40d173]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Sweden: Swedish National Council on Medical Ethics [clinicaltrials_resource:7b579c2e095b3e6581b6c36c20ec6569]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

reference [clinicaltrials_vocabulary:reference]

12133653 [pubmed:12133653]

secondary id [clinicaltrials_vocabulary:secondary-id]

Sponsor: Orion Pharma

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Orion Corporation, Orion Pharma [clinicaltrials_resource:56914c11ae481d6452d21ddca88db97d]

start date [clinicaltrials_vocabulary:start-date]

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00219388 study design [clinicaltrials_resource:61c7850470f0b6d41fcab98237044b73]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00219388

verification date [clinicaltrials_vocabulary:verification-date]

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00219388

http://www.w3.org/2001/XMLSchema#string

title

Efficacy and Safety of Treatme ...... nsated Heart Failure Patients.

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Efficacy and Safety of Treatme ...... . [clinicaltrials:NCT00219388]

@en